References
- 1. Zemin C, EC. M. Pathogenesis of diabetic nephropathy. J Diabetes Invest 2011;2:243-7.
- 2. Fard AA, Abbasnezhad P, Makhdomi K, et al. Association of Serum Prolactin Concentrations with Renal Failure in Diabetic Patients. Romanian Journal of Diabetes Nutrition and Metabolic Diseases. 2017;24(3):179-85.
- 3. Ibrahim HN, TH. H. Diabetic nephropathy. J Am Soc Nephrol. 1997;8:487-93.
- 4. Atkins R, Zimmet PI-I. World Kidney Day Steering Committee: Diabetic kidney disease: Act now or pay later. Nat Rev Nephrol. 2010;6:134-6.
- 5. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem. 1996;271(17):10079-86.
- 6. Kato M, Wang H, Kainulainen V, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nature medicine. 1998;4(6):691-7.
- 7. Makino H, Ikeda S, Haramoto T, Ota Z. Heparan sulfate proteoglycans are lost in patients with diabetic nephropathy. Nephron. 1992;61(4):415-21.
- 8. Kanwar YS, Farquhar MG. Presence of heparan sulfate in the glomerular basement membrane. Proceedings of the National Academy of Sciences. 1979;76(3):1303-7.
- 9. Shafat I, Ilan N, Zoabi S, Vlodavsky I, Nakhoul F. Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PloS one. 2011;6(2):e17312.
- 10. Rops AL, Van den Hoven MJ, Veldman BA, et al. Urinary heparanase activity in patients with Type 1 and Type 2 diabetes. Nephrology Dialysis Transplantation. 2012;27(7):2853-61.
- 11. Rosenzweig L, Kanwar Y. Removal of sulfated (heparan sul-fate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125I-bovine serum albumin. Lab Invest. 1982;47(2):177-84.
- 12. Kolset S, Reinholt F, Jenssen T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem. 2012;60(12):976-86.
- 13. Lauver DA, Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovascular Therapeutics. 2006;24(3-4):214-26.
- 14. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexide. Med Res Rev. 1998;18(1):1-20.
- 15. Dedov I, Shestakova M, Vorontzov A, Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 1997;12(11):2295-300.
- 16. Skrha J, Perusicová J, Pont’uch P, Oksa A. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract. 1997;38(1):25-31.
- 17. Lewis EJ, Lewis JB, Greene T, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kid Dis,2011;58(5):729-36.
- 18. Reddi AS, Ramamurti R, Miller M, et al. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol. 1991;45(119-131).
- 19. Sugimoto H, Grahovac G, Zeisberg M, Kalluri R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes. 2007;56(7):1825-33.
- 20. Brosius FC, Alpers CE, Bottinger EP, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2503-12.
- 21. Conde-Knape K. Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab Res Rev. 2001;17(6):412-21.
- 22. Vanden Born J, Van Kraats AA, Hill S, et al. Vessel wall heparan sulfate and transcapillary passage of albumin in experimental diabetes in the rat. Nephrol Dial Transplant. 1997;12(2):27-31.
- 23. De Lima CR, Aguiar JA, Michelacci YM. Reduced urinary excretion of sulfated polysaccharides in diabetic rats. Biochim Biophys Acta.2005;1741(1-2):30-41.
- 24. Cadaval RA, Kohlman O, Michelacci YM. Urinary excretion of glycosaminoglycans and albumin in experimental diabetes mellitus. Glycobiology. 2000;10(2):185-92.
- 25. Yavuz DG, Ersöz HO, Tuncel M et al. Effects of Aminoguanidine on Glomerular Basement Membrane Thickness and Anionic Charge in a Diabetic Rat Model. Int Jnl Experimental Diab Res. 2001;2:225-32.
- 26. McAuliffe A, Fisher E, McLennan S, et al. Urinary glycosaminoglycan excretion in NIDDM subjects: Its relationship to albuminura. Diabetic medicine. 1996;13(8):758-63.
- 27. Popławska-Kita A, Mierzejewska-Iwanowska B, Szelachowska M et al. Glycosaminoglycans urinary excretion as a marker of the early stages of diabetic nephropathy and the disease progression. Diabetes Metab Res Rev 2008;24(4):310-7.
- 28. Cechowska-Pasko M, Pałka J, Bańkowski E. Decrease in the glycosaminoglycan content in the skin of diabetic rats. The role of IGF-I, IGF-binding proteins and proteolytic activity. Mol Cell biochem. 1996;154(1):1-8.
- 29. Juretić D, Krajnović V, Lukac-Bajalo J. Altered distribution of urinary glycosaminoglycans in diabetic subjects. Acta diabetol. 2002;39(3):123-8.
- 30. Harvey SJ, Miner JH. Breaking down the barrier: evidence against a role for heparan sulfate in glomerular permselectivity. J Am Soc Nephrology. 2007.